WALTHAM–Akagera Medicines has received an additional $7.8 million grant from the Gates Foundation to advance development of an experimental mRNA vaccine designed to prevent tuberculosis, bringing the foundation’s total funding commitment to the program to approximately $9.79 million.
The company announced Wednesday that the expanded funding will support manufacturing and preclinical safety studies needed to prepare its dendritic cell-targeted vaccine candidate for an initial human clinical trial.
The new award totals $7,806,414 and builds on an earlier grant awarded in 2023. The combined funding commitment now stands at $9,791,826.
Akagera is developing a vaccine that combines messenger RNA (mRNA) technology with specially engineered lipid nanoparticles designed to deliver vaccine components directly to dendritic cells, which play a central role in activating the immune system.
The approach is intended to generate strong and durable T-cell responses against tuberculosis while potentially reducing the amount of vaccine required and improving tolerability.
The latest funding will allow Akagera to move the program beyond early laboratory research and begin preparations for a Phase 1 clinical trial.
The company plans to use the grant for Good Manufacturing Practice (GMP) production of clinical trial materials, toxicology studies conducted under Good Laboratory Practice (GLP) standards and additional safety assessments required for regulatory submissions.
The work will also support preparation of an Investigational New Drug (IND) application or equivalent regulatory filing needed before human testing can begin.
“This expanded support from the Gates Foundation marks the transition of our TB vaccine program from proof of concept to clinical readiness,” said Daryl Drummond, Ph.D., Co-Founder and Chief Scientific Officer of Akagera Medicines. “Targeting mRNA delivery to dendritic cells lets us focus on the immune response where it matters most for TB. With manufacturing and IND-enabling toxicology now funded, we have a clear path to our first-in-human study.”
Tuberculosis remains one of the world’s deadliest infectious diseases, causing more than one million deaths annually.
The disease disproportionately affects populations in low- and middle-income countries, where access to preventive vaccines, diagnostic testing and treatment can be limited.
The Bacillus Calmette-Guérin (BCG) vaccine, developed more than a century ago, remains the only licensed vaccine against tuberculosis. However, its effectiveness against pulmonary tuberculosis varies, particularly among adolescents and adults.
Researchers have identified the need for more effective vaccines targeting these populations, which account for a substantial share of tuberculosis transmission.
Akagera’s experimental vaccine uses mRNA encoding antigens from Mycobacterium tuberculosis, the bacterium responsible for the disease.
The mRNA is packaged inside lipid nanoparticles engineered to preferentially deliver their contents to dendritic cells, which process antigens and help initiate immune responses.
By directing vaccine delivery to these cells, researchers hope to stimulate the immune mechanisms believed to be important for long-term protection against tuberculosis.
Under the original Gates Foundation grant, Akagera established preliminary evidence supporting the feasibility of its vaccine technology.
Preclinical studies involving animal models demonstrated immune responses to a vaccine candidate encoding nine distinct tuberculosis antigens.
Laboratory experiments also showed that human blood immune cells could recognize the tuberculosis antigens produced by the vaccine candidate.
The expanded grant will support further development of the technology and the safety testing required before the vaccine can be evaluated in humans.
“Tuberculosis falls hardest on the communities with the least access to new medicines,” said Michael Fairbanks, Co-Founder and Executive Chairman of Akagera Medicines. “The Gates Foundation’s continued funding lets us advance a vaccine designed from the start for the people and places that need it most, alongside our long-acting TB therapeutic, AKG-100.”
In addition to its vaccine program, Akagera is developing AKG-100, an investigational long-acting intravenous treatment for drug-susceptible and drug-resistant tuberculosis.
The company reported positive initial human clinical data from a single-ascending-dose study of AKG-100 in July 2026.
Akagera is also developing lipid nanoparticle-based medicines and vaccines targeting other infectious diseases, including respiratory syncytial virus (RSV), influenza, Lassa fever and HIV.
Headquartered in Waltham, Massachusetts, Akagera operates a wholly owned subsidiary in Kigali, Rwanda, and is majority-owned by the people of Rwanda, according to the company.
The new Gates Foundation funding represents another step toward bringing Akagera’s tuberculosis vaccine into clinical development, although additional manufacturing, toxicology and regulatory work must be completed before human trials can begin.


